These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-000775-34 A double-blind, randomised, parallel group study to evaluate the safety, tolerability and efficacy of TAK-475 alone or co-administered with atorvastatin in patients with primary dyslipidemia 2007-05-15 due-trials
Other 2004-001720-21 A Phase III, multi-center, randomized, double-blind comparator study to evaluate the efficacy and safety of 50 mg and 100 mg of TAK-013 tablets administered twice daily versus 3.75mg of Leuprolide adm... not-yet-due
Other 2004-001721-13 A Phase III, multi-center, randomized, double-blind study to evaluate the efficacy and safety of 50 mg and 100 mg of sufugolix (TAK-013) tablets administered twice daily versus placebo for 12 weeks in... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2004-002157-30 A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Oral TAK-715 in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis 2005-11-14 bad-data
Completed, but no date, and reported results 2004-002231-92 A Phase II Study of AP23573, an mTOR Inhibitor, in Patients with Advanced Sarcoma bad-data
Reported results 2004-002567-24 A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis 2007-04-04 due-trials
Reported results 2004-003829-28 An open-label investigation into the tolerability and pharmacokinetic / pharmacodynamic effects of sufugolix (TAK-013), at a dosage of 100mg twice-daily, during six months treatment of pre-menopausal ... 2005-08-31 due-trials
Reported results 2004-003962-14 Candesartan "added" Treatment for Optimisation of Heart Failure (HF) Therapy - Effects on BNP and other HF associated Parameters. An open, non-controlled and multicentre trial 2006-08-24 due-trials
Reported results Terminated 2004-004226-28 Effects of Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Heart Disease at High Risk for Cardiovascular Complications 2006-11-21 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-004350-91 A multicentre, randomised, double-blind, double-dummy, placebo-controlled study to evaluate the safety and efficacy of ramelteon compared to placebo with zopiclone as a reference arm in adults with ch... 2006-10-02 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-004351-20 A randomised, double-blind, placebo-controlled study to determine the long-term efficacy and safety of ramelteon in adults with chronic insomnia. 2006-12-15 bad-data
Reported results 2004-004463-30 Effects of Pioglitazone in Combination with Atorvastatin in Comparison to Atorvastatin treatment alone on Intima-Media Thickness in patients at Risk for Vascular Complications 2006-10-23 due-trials
Reported results 2004-005094-29 A Phase II Study of AP23573, a mTOR Inhibitor, in Female Adult Patients with Recurrent or Persistent Endometrial Cancer 2010-01-15 due-trials
Reported results 2005-000730-20 An open label, international, multi centre, parallel group, phase III b, randomised trial, investigating lumbar spine Bone Mineral Density (BMD) changes in postmenopausal women with primary osteoporos... 2011-01-14 due-trials
Reported results Terminated 2005-001306-87 EFFECTS OF CANDESARTAN CILEXETIL VS STANDARD THERAPY ON SERUM LEVELS OF BRAIN NATRIURETIC PEPTIDE IN PATIENTS SUFFERING FROM CHRONIC HEART FAILURE WITH DEPRESSED AND PRESERVED SYSTOLIC FUNCTION 2008-05-27 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-002313-21 A placebo-controlled, double-blind, randomized study to evaluate the efficacy and safety of TAK-475 50mg and 100mg versus placebo, when co-administered with simvastatin 20mg or 40mg in subjects with p... 2007-03-02 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-002315-25 A double-blind, double dummy, randomized, parallel group, multi-centre Phase III study to evaluate the efficacy and safety of TAK-475 100 mg and TAK-475 100 mg administered in combination with ezetimi... 2008-01-09 bad-data
Reported results 2005-002316-24 A placebo-controlled, double-blind, randomised study to evaluate the efficacy and safety of TAK-475 100mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy. 2007-05-09 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-003561-16 A Pivotal, Multicentre, Multinational, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-242 in Adults with Severe Sepsis 2007-02-01 bad-data
Completed, but no date, and reported results Terminated 2005-003626-26 A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous fami... bad-data
Reported results 2005-003819-71 A double-blind, placebo-controlled study followed by a repeat dosing phase to assess the efficacy and safety of DX-88 recombinant plasma kallikrein inhibitor for the treatment of acute attacks of ... 2007-09-21 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-004667-36 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with a Sulfonylurea in Subjects with Type 2 Diabe... 2007-05-10 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-004668-22 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with Metformin in Subjects with Type 2 Diabetes 2007-07-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-004669-40 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with Pioglitazone in Subjects with Type 2 Diabete... 2007-08-02 bad-data
Reported results 2005-004670-24 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) Compared with Placebo in Subjects with Type 2 Diabetes 2007-07-05 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-004671-38 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with Insulin in Subjects with Type 2 Diabetes 2007-05-17 bad-data
Reported results 2005-004672-20 A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects with Type 2 Diabetes 2011-11-15 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-004876-19 A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 100 mg or Placebo When Co-Administered With High Dose Statin Therapy in Subjects With Primary Hypercholesterolemia 2008-03-28 bad-data
Reported results 2005-004944-30 An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection (Hematide™) in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney... 2016-10-24 due-trials
Reported results 2005-005641-19 3 Months, Open-Label, Parallel-Group Study of the Pharmacodynamics, Pharmacokinetics and Safety of TAP-144SR 1-month Depot Gelatin-Free vs. Gelatin-Containing Formulation in Female Patients with Uteri... 2008-12-19 due-trials
Reported results 2005-005863-26 A Phase 2, double blind, placebo controlled, dose-ranging study in subjects with post herpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability and pharmacokinetics of four doses of TAK-... 2008-02-05 due-trials
Reported results 2005-006165-14 A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study of the Efficacy, Safety, and Pharmacokinetics of MLN3897 in Patients with Rheumatoid Arthritis Taking Methotrexate 2007-09-12 due-trials
Reported results 2006-000694-30 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS) in Subjects with Type 2 D... 2008-03-17 due-trials
Completed, but no date, and reported results 2006-000725-54 Double-blind, randomized, multicenter, parallel-group study to evaluate the effects of pioglitazone on metabolic syndrome in patients with type 2 diabetes treated with metformin bad-data
Reported results 2006-001998-25 Double-blind, randomised trial to investigate the antihypertensive and metabolic effects of candesartan in insulin-resistant obese patients with a hypertension not adequately controlled by previous be... 2008-09-24 due-trials
Reported results 2006-002237-20 Pilot trial studying the Effects of Pioglitazone in Comparison to Placebo on Myocardial Function and Oxidative Stress in Patients with Type II Diabetes and Insulin Resistance undergoing elective PTCA 2010-01-25 due-trials
Reported results 2006-002271-41 Effects of Pioglitazone in Combination with Glimepiride in Comparison to Glimepiride Monotherapy on Metabolic Control in Patients with Type 2 Diabetes mellitus 2008-12-16 due-trials
Reported results 2006-002354-30 Effect of Acute Insulin Intervention followed by Pioglitazone and Metformin Treatment on Metabolic Parameters in Type 2 Diabetic Patients with inadequate Metabolic Control 2007-01-23 due-trials
Reported results 2006-003054-26 A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate the Safety and Efficacy of Oral TAK-783 in the Treatment of the Signs and Symptoms of in Subjects with Rheumatoid Arth... 2009-02-24 due-trials
Reported results 2006-004028-35 Effect of Pioglitazone compared to a combination therapy with Ramipril and to a Ramipril monotherapy on low grade inflammation and vascular function in patients with increased cardiovascular risk and ... 2008-05-21 due-trials
Reported results 2006-004455-37 Effects of a Pioglitazone/ Metformin Fixed Combination in Comparison to Metformin in Combination with Glimepiride on Diabetic Dyslipidemia 2009-05-13 due-trials
Reported results 2006-005492-17 A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of SYR-322 plus Pioglitazone HCl (Actos), SYR-322 Alone or Pioglitazone HCl Alone in Subjects with Type 2 Diabetes 2008-02-13 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-006025-73 A Multicenter, Randomized, Double-Blind Study to Determine the Efficacy and Safety of the Addition of SYR-322 25 mg versus Dose Titration from 30 mg to 45 mg of ACTOS Pioglitazone HCl in Subjects wit... 2009-06-05 bad-data
Reported results 2007-000240-27 A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Weekly Treatment with SYR-472 in Subjects with Type 2 Diabetes. 2008-03-13 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-000403-15 A Randomized, Double-Blind, Placebo-Controlled, Polysomnography plus Outpatient Study to Determine the Safety and Efficacy of 4 mg Ramelteon in Adults with Chronic Insomnia 2008-03-28 bad-data
Reported results 2007-000486-38 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing SYR-322 Alone and Combination SYR-322 with Pioglitazone versus Placebo on Postprandial Lipids in Subjects w... 2009-12-17 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-001489-34 A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg versus Placebo in Subjects with Hypercholesterolemia, With an Optional Open-Label Extension 2008-03-28 bad-data
Reported results 2007-002583-10 A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Ramipril in Subjects With Essential Hypertension 2009-04-21 due-trials
Ongoing, reported early 2007-002875-15 A Single-Center, Randomized, Double-Blind, Double-Dummy Placebo Controlled, Cross-Over Study to Investigate the Next Morning Effects of Ramelteon (8mg), Zopiclone (7.5mg) and Placebo on Actual Driving... not-yet-due
Reported results Terminated 2007-003070-26 Candesartan “added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, pa... 2008-10-31 due-trials
Completed, but no date, and reported results 2007-003077-44 EffectS of PiogLitazone on ENDOthelial progenitoR cells in type 2 diabetic patients with vascular complications - The SPLENDOR Study bad-data
Reported results 2007-003462-18 A Pivotal Trial to Determine the Efficacy and Safety of AP23573 (Ridaforolimus) when Administered as Maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcomas 2014-09-18 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-005687-27 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of TAK-242 Versus Placebo in Subjects With Sepsis Induced Cardiovascular and Respiratory Failure 2009-02-20 bad-data
Reported results 2007-006706-14 Impact of Pioglitazone, Metformin and the combination of both on cardiovascular risk in insulin-treated patients with Type 2 diabetes – The PIOcomb Study 2010-07-28 due-trials
Reported results 2007-006744-21 Comparison of the Effects of Pioglitazone vs. Placebo when given in addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus and Renal Failure – The PIOren Study 2010-06-29 due-trials
Reported results 2008-000091-24 A Phase 2, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes 2010-06-21 due-trials
Reported results 2008-000634-53 A randomized phase II trial of deforolimus (AP23573; MK-8669) compared to progestin in female adult patients with advanced endometrial carcinoma following one line of chemotherapy 2012-07-09 due-trials
Reported results 2008-000959-10 A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Subjects with Type 2 Diabetes 2010-08-30 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-001580-11 A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder 2009-08-13 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-001581-91 A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 in Subjects With Major Depressive Disorder 2010-08-23 bad-data
Reported results 2008-001766-90 A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of a Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety ... 2009-07-07 due-trials
Reported results 2008-001971-30 A Phase II Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination with Trastuzumab for Patients with HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer 2011-05-10 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-002782-32 A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe ... 2013-12-09 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-002783-33 A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe C... 2014-02-19 bad-data
Reported results 2008-002784-14 A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn?s Disease Estudio abierto, de fase 3 para determinar la eficacia y ... 2017-10-31 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-003458-13 A Phase 2 Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Subjects Previously Treated With Epoetin 2010-05-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-003459-64 A Phase 2 Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Subjects with Chronic Renal Failure Who Are on Hemodialysis or Do Not Require Dialysis and ... 2009-12-24 bad-data
Reported results 2008-004218-28 A Phase 3, Double-Blind, Randomized, Factorial, Efficacy and Safety Study of TAK 491 Plus Chlorthalidone Fixed-Dose Combination in Subjects with Moderate to Severe Hypertension 2010-07-10 due-trials
Reported results 2008-006906-41 A Modified Case Control Study To Identify Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure To Lapaquistat Acetate 2010-05-22 due-trials
Ongoing, reported early 2008-006977-34 A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients with Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome not-yet-due
Ongoing, reported early 2008-006979-72 A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients with Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Car... not-yet-due
Reported results 2008-006981-27 A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gast... 2014-04-25 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-007444-34 A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination with Metformin in Su... 2012-10-17 bad-data
Reported results 2008-008260-28 A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose... 2011-11-17 due-trials
Trial is outside EEC, and reported results 2009-011221-13 A Comparative, Randomized, Open-Label, Multi-Center, Single Dose Pharmacokinetic, Pharmacodynamic and Safety Study of Alogliptin (12.5 mg and 25 mg) Between Children, Adolescents, and Adults with Type... bad-data
Listed as ongoing, but also has a completion date and reported results 2009-011222-34 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabet... 2013-06-18 bad-data
Ongoing, reported early 2009-011428-79 Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritonea... not-yet-due
Reported results 2009-011776-30 Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg plus Hydrochlorothiazide 25 mg in Patients with Severe Hypertension 2010-06-17 due-trials
Reported results 2009-012652-24 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus Metformin, Alogliptin Alone, or Metformin Alone in Subjects with Type 2 Diabet... 2011-06-30 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-013056-71 Ensayo abierto, aleatorizado, multicentrico, controlado con grupo paralelo para evaluar la eficacia y seguridad de TachoSilâ frente a la práctica habitual en técnicas de sellado de duramadre para la... 2013-09-06 bad-data
Trial is partly outside EEC, and reported results 2009-013165-25 A Comparative Single-Dose Pharmacokinetic and Safety Study of TAK-491 Between Infants, Children, and Adolescents with Hypertension and Healthy Adults 2013-09-09 bad-data
Reported results 2009-016488-12 A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn’s Disease 2014-01-30 due-trials
Exempt, with results 2009-017668-18 A Phase 1/2, Open-Label Study in Men with Prostate Cancer to Assess the Safety, Pharmacokinetics, and Testosterone-Lowering Efficacy of TAK-448, Administered as a 1 Month Depot, Including a Randomized... 2011-09-09 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2010-018661-35 A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Pr... 2016-04-07 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-018662-23 A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK 700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That ... 2016-02-29 bad-data
Reported results 2010-019685-87 Effect of roflumilast on exacerbation rate in patients with COPD treated with fixed combinations of LABA and ICS. A 52-week, randomised double-blind trial with roflumilast 500 ?g versus placebo Efe... 2014-07-31 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-020414-28 A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia 2019-01-17 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-022257-41 A Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Lu AA21004 in Patients with Major Depressive Disorder 2012-04-25 bad-data
No trial status on register 2010-022716-39 A 3-Part Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Subcutaneous Ecallantide in Prepubertal Paediatric Patients Experiencing Acute Attacks of Hereditary Angioedema bad-data
Reported results 2010-023098-21 A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-... 2012-10-11 due-trials
Reported results 2010-023772-71 An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a Next-Generation Proteasome Inhibitor, Administered in Combination with a Standard Care Regimen of Melphalan and Prednis... 2016-12-30 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-024215-14 A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Sperimentazio... 2018-07-06 bad-data
Reported results 2011-000220-16 A Phase-3 Randomized, Double-Blind, Efficacy and Safety Study Evaluating the Fixed Dose Combinations of TAK-491 Plus Chlorthalidone (40/12.5 mg and 40/25 mg) in Subjects With Grades 2 or 3 Essential H... 2013-01-24 due-trials
Reported results 2011-000582-13 A 16-week, randomized, placebo-controlled, double blind, and parallel group trial to assess the anti-inflammatory effects of Roflumilast in chronic obstructive pulmonary disease The ROBERT study (Rofl... 2016-02-11 due-trials
Ongoing 2011-000609-32 A Multicenter, Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab and Vincristine not-yet-due
Reported results 2011-000683-99 Control of moderate or severe asthma with 160, 320 and 640μg ciclesonide/day. A one-year randomised, double-blind, multicenter trial. 2014-11-17 due-trials
Reported results 2011-001240-29 A Phase 1/2 Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma 2018-04-12 due-trials
Reported results 2011-001731-24 A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Glimepiride When Used in Combination with Metformin... 2014-04-24 due-trials
Reported results 2011-001732-37 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and wi... 2014-05-05 due-trials
Reported results Terminated 2011-001752-10 A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Placebo and Sitagliptin 100 mg When Us... 2013-12-27 due-trials
Reported results 2011-002741-35 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared with Placebo in Subjects with Type 2 Diabetes 2013-07-05 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-003545-18 A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Periphera... 2018-04-16 bad-data
Reported results 2011-005298-22 A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects with Major Depressive Di... 2014-02-05 due-trials
Other 2011-005450-60 A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma Studio di Fase 3, randomizzato, in aperto su A+AVD rispetto ad... not-yet-due
Listed as ongoing, but also has a completion date 2011-005468-10 A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refracto... 2020-09-11 bad-data
Ongoing 2011-005496-17 A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed a... not-yet-due
Exempt, with results 2011-005718-12 A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113 Estudio en fase 1/2 sobre la seguridad, tolerabilidad, far... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2012-000136-26 A Phase 2, Open-Label, Single-Arm, Multidose Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer 2015-01-21 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-001355-38 A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Studio di Fase III, Randomizzato, in Aperto, c... 2013-10-18 bad-data
Reported results Terminated 2012-001357-10 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1 mg and ... 2014-07-30 due-trials
Exempt, with results 2012-001539-30 A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients with Castration-Resistant Prostate Cancer 2016-09-01 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2012-001680-72 A Phase 2 Open-Label, Multicenter, 4-Week Study to Assess the safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed- Release Capsules for Relief of Heartburn, in Adolescent ... 2014-01-21 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-001681-15 A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed- Release Capsules for Healing of Erosive Esophagitis and Maintenance... 2014-11-10 bad-data
Reported results 2012-002064-27 A Phase 2, Randomized, Double-blind, 4-week Cross-over Trial to Investigate The Effect of a Once-daily Combination of 500 µg Roflumilast plus 10 mg Montelukast versus 10 mg Montelukast Alone on Pulmon... 2013-10-24 due-trials
Exempt, with results 2012-002998-62 A Randomized, Single-Center, Observer-Blind, Vehicle- and Active Comparator-Controlled Phase 1b Study to Assess the Effect and Local Safety and Tolerability Of Roflumilast and BYK321084 – Phosphodiest... 2013-10-30 not-yet-due
Reported results 2012-003000-12 A Phase 2a, 15-Day, Randomized, Parallel Group, Double-Blind, Multi-Centre, Vehicle Controlled Trial to Assess the Efficacy and Local Safety of a Cream Containing 0.5% Roflumilast - a Phosphodiesteras... 2014-03-18 due-trials
Reported results 2012-003111-58 A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer’s Di... 2018-08-07 due-trials
Ongoing 2012-004128-39 A Phase 4, Open?label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Estudio de fase 4, abierto, con un único grupo de trat... not-yet-due
Ongoing 2012-005653-22 TachoSil patch application as replacement of closed suction wound drainage by parotid gland surgery; a prospective study. TachoSil applicatie als vervanging van wonddrainage bij parotischirurgie; e... not-yet-due
Ongoing, reported early 2012-005732-28 A multicentre, open-label switch study to investigate the necessity of dose adjustment after switching from L-Thyroxine Christiaens® to the new levothyroxine sodium test formulation in (near) total th... not-yet-due
Reported results Terminated 2013-000007-17 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50mg Compared With Placebo as an Add-On to Glimepiride in ... 2013-12-27 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-000232-10 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy 2020-03-12 bad-data
Ongoing 2013-000326-54 A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagno... not-yet-due
Reported results Terminated 2013-000542-19 A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Sitagliptin 100 mg When Used in Combina... 2013-12-27 due-trials
Reported results Terminated 2013-000886-35 A Phase 2 Randomized, Placebo-Controlled, Double-Blind Parallel-Group, Multicenter Study to Evaluate the Glycemic Effects and Safety of Fasiglifam 25 mg Twice Daily and 50 mg Once Daily on Glycemic Co... 2013-12-27 due-trials
Completed, but no date, and reported results 2013-001419-64 A Phase II, Randomized, Controlled, Double-Blind, Dosage and Adjuvant Justification, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Adjuvant... bad-data
Listed as ongoing, but also has a completion date and reported results 2013-001788-21 A multicenter, randomized, double-blind phase 3 study to evaluate tolerability and pharmacokinetics of 500μg roflumilast once daily with an up-titration regimen in COPD, including an open-label down-t... 2015-11-30 bad-data
Ongoing 2013-002076-41 A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant not-yet-due
Listed as ongoing, but also has a completion date and reported results 2013-002134-21 A Randomized Phase 2 Study of AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated with Crizotinib 2020-02-27 bad-data
Reported results 2013-002302-32 An Open-label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma 2017-03-23 due-trials
Reported results 2013-002805-76 A 24-week randomized, double-blind, placebo-controlled, phase 2 dose finding study to evaluate the efficacy and safety of 3 doses of namilumab (20 mg, 80 mg and 150 mg) in combination with methotrexat... 2016-11-16 due-trials
Reported results 2013-002806-30 A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding and Proof of Concept Study, to Assess the Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Namilum... 2016-02-23 due-trials
Reported results 2013-003113-17 An Open-Label, Phase 2 Study to Evaluate the Oral Combination of MLN9708 With Cyclophosphamide and Dexamethasone In Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiri... 2018-06-29 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-003713-18 A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Sm... 2017-07-10 bad-data
Reported results 2013-004984-30 A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Compl... 2018-05-08 due-trials
Trial is partly outside EEC, and reported results 2014-000778-20 A Phase II, Randomized, Double-Blind, Dosage, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine combined with Aluminum Hydroxide adjuvant in Ch... 2018-06-20 bad-data
Reported results Terminated 2014-000804-88 A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC) 2016-01-15 due-trials
Listed as ongoing, but also has a completion date and reported results 2014-000805-11 A Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC) 2016-01-15 bad-data
Ongoing 2014-001394-13 A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Tr... not-yet-due
Listed as ongoing, but also has a completion date 2014-001617-12 A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses 2018-01-16 bad-data
Exempt 2014-001642-16 A Phase 1, Randomized, Open-Label, Parallel-Design, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Capsules in Infants Aged 1 to 11... 2020-02-10 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2014-001921-34 A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast... 2018-07-03 bad-data
Reported results Terminated 2014-002155-25 An Open-Label, Phase 2a Study to Evaluate the Pharmacodynamics of Different Dosing Regimens of TAK-448, a Kisspeptin Agonist, in Male Overweight/Obese Subjects With Hypogonadotropic Hypogonadism 2015-12-04 due-trials
Reported results 2014-002945-23 A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs Adal... 2016-11-01 due-trials
Reported results 2014-003509-13 An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV 2018-02-21 due-trials
Listed as ongoing, but also has a completion date and reported results 2014-003942-28 Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying In... 2017-02-23 bad-data
Listed as ongoing, but also has a completion date 2014-004281-25 A Phase 1b/Adaptive Phase 2 Study of Docetaxel With or Without MLN1117 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer 2016-09-15 bad-data
Other 2014-004506-15 A Phase 2, Double-Blind, 12 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 1 to 11 Y... not-yet-due
Other 2014-004507-73 A Phase 2, Double Blind, Up to 40 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophag... not-yet-due
Reported results Terminated 2014-005142-21 A Multicenter, Randomized, Double Blind, Placebo Controlled, Proof of Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Weekly Subcutaneous MLN1202, in Improving Diabetic Nephropathy Subje... 2015-11-17 due-trials
Completed, report not yet due 2014-005394-37 A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3K? Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, R... 2020-10-30 not-yet-due
Reported results 2014-005619-18 A Randomized, Open-Label, 2-Way Cross-over, Phase 4 Study to Evaluate Subject Preference and Acceptability of a New Formulation of Calcichew D3 in Adult Patients Eligible for Calcium and Vitamin D Sup... 2015-08-21 due-trials
Ongoing 2015-000208-25 A Multicenter, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 Diabetes Mellitus not-yet-due
Ongoing 2015-000221-37 A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients with Higher-Risk Myelodysplastic S... not-yet-due
Reported results 2015-000480-14 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, with a Vedolizumab IV Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects Wi... 2018-10-08 due-trials
Reported results 2015-000481-58 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn... 2019-10-14 due-trials
Ongoing 2015-000482-31 A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects with Ulcerative Colitis and Crohn?s Disease Estudio abierto, de fase IIIb para est... not-yet-due
Reported results 2015-000852-12 A Randomized Double-Blind Phase 4 Study to Evaluate the Safety and Proportion of Subjects With Fistula Healing in 2 Dose Regimens of Entyvio (Vedolizumab IV) in the Treatment of Fistulizing Crohn's Di... 2018-11-14 due-trials
Listed as ongoing, but also has a completion date and reported results 2015-000939-33 A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects With Ulcerative Colitis 2019-03-11 bad-data
Reported results 2015-001154-14 A Randomized, Double-Blind, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once Daily Oral Vonoprazan 20 mg or Vonoprazan 40 mg Compared to Esomeprazole 40 mg for the Treatment... 2018-10-12 due-trials
Listed as ongoing, but also has a completion date 2015-001318-92 A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib 2020-11-26 bad-data
Completed, report not yet due 2015-002133-22 A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced... 2020-10-13 not-yet-due
Listed as ongoing, but also has a completion date 2015-003447-19 A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer 2020-12-21 bad-data
Listed as ongoing, but also has a completion date and reported results 2015-003472-78 A Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Evaluate the Efficacy and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis 2021-02-09 bad-data
Reported results Terminated 2015-003612-20 An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or ... 2019-11-25 due-trials
Reported results 2015-003943-20 HELP Study™: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX 2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE) 2017-04-13 due-trials
Ongoing 2015-004112-38 An Open-Label Study of Brentuximab Vedotin+Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma Estudio abierto con Brentuximab Vedoti... not-yet-due
Reported results 2015-005255-27 HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) 2019-10-31 due-trials
Ongoing 2016-000678-40 Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn’s Disease not-yet-due
Ongoing 2016-001271-68 A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer not-yet-due
Ongoing 2016-001681-28 An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies. not-yet-due
Reported results 2016-002985-30 An Open-Label, Dose-Finding Study of Vedolizumab IV for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Patients who Have Undergone Allogeneic Hematopoietic Stem C... 2018-06-04 due-trials
Reported results 2016-003716-12 Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After at Least 2 Prior Lines of Chemotherapy 2019-12-17 due-trials
Ongoing 2016-004288-37 A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects who have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine not-yet-due
Ongoing 2016-004742-28 A Phase 2, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma not-yet-due
Other 2017-000318-40 A Phase 3, Randomized, Controlled, Open-Label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syn... not-yet-due
Reported results 2017-001071-23 A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular Hepa... 2019-07-09 due-trials
Reported results Terminated 2017-001084-20 A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Subjects With... 2019-11-06 due-trials
Other 2017-001739-38 A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Safety, Tolerability, and pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult Subj... not-yet-due
Ongoing 2017-002182-21 A Phase 2b, Extension Study to Determine the Long-term Safety of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease. (Long-term Safety With Vedolizumab IV in Pediatric Sub... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2017-002231-41 A Phase 2, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Safety and Tolerability of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease (A... 2020-05-26 bad-data
Reported results Terminated 2017-002232-16 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-653 in the Treatment of Subjects with Treatment-Resistant Depression 2018-02-01 due-trials
Ongoing 2017-002491-10 Postauthorization Safety Study of the Long-Term Safety and Efficacy of Repeat Administration of Darvadstrocel in Patients With Crohn’s Disease and Complex Perianal Fistula not-yet-due
Reported results Terminated 2017-003206-41 A Phase 2b, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous TAK-954 in Critically Ill Patients With Enteral Feeding Intole... 2018-11-02 due-trials
Completed, report not yet due 2017-003471-54 A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose levels of TAK-831 in Adjunctive Treatment of... 2021-01-12 not-yet-due
Ongoing 2017-003977-32 A Phase 2, Open-Label Study of Ixazomib + Daratumumab + Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) not-yet-due
Ongoing 2018-000397-30 A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia... not-yet-due
Ongoing 2018-000635-27 Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib not-yet-due
Other 2018-000821-29 A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-label ... not-yet-due
Ongoing 2018-001275-21 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally Acting Dopamine Rec... not-yet-due
Ongoing 2018-001957-29 A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIGTM) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive on–Small-Cell Lung Cancer Patients Who Have Progressed o... not-yet-due
Other 2018-002141-11 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease in Subjects Underg... not-yet-due
Completed, reported early 2018-002484-25 A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-935 (OV935) AS AN ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS WITH DEV... 2020-06-09 not-yet-due
Ongoing 2018-003318-42 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postoperat... not-yet-due
Completed, report not yet due Terminated 2018-003907-20 Open-Label Phase 1 Study to Assess the Maximum Tolerated Dose, Pharmacokinetics, and Safety of Ixazomib Administered Intravenously to Pediatric Patients Aged 0 to <18 Years With Relapsed or Refractory... 2020-09-18 not-yet-due
Trial is outside EEC, and reported results 2018-003978-28 A Phase II, Double-Blind, Controlled Trial to Assess the Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Subjects Aged Between 2 and ... bad-data
Trial is outside EEC 2018-003979-34 Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Childr... bad-data
Trial is outside EEC, and reported results 2018-003980-77 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of Subcutaneous Administration of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescen... bad-data
Completed, report not yet due 2018-004750-21 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Adult Subjects With Chronic Complex Regional Pa... 2020-10-28 not-yet-due
Ongoing 2019-000333-39 A Follow-up of a Phase 3 Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel in the Treatment of Complex Perianal Fistula in Subjects With Crohn’s Disease Who Have Participated in ADM... not-yet-due
Other 2019-000886-19 A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn’s Dise... not-yet-due
Trial is outside EEC, and reported results 2019-001198-10 A Phase 3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Inductio... bad-data
Trial is outside EEC, and reported results 2019-001199-12 Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Examine the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction... bad-data
Other 2019-001703-20 A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema with ... not-yet-due
Other 2019-001845-42 A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Ex... not-yet-due
Other 2019-002549-39 A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphobla... not-yet-due
Other 2019-003117-33 A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit ... not-yet-due
Ongoing 2019-003383-47 A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis Studio di fase 2, randomizzato, controllato ... not-yet-due
Ongoing 2019-004103-12 A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Persistent/Chronic Primary Immune Thrombocytopenia not-yet-due
Other 2019-004823-20 An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema with Normal C1-Inhibitor (C1-INH) not-yet-due
Ongoing 2020-000777-24 A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With... not-yet-due
Other 2020-003193-48 A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects with Crohn’s Disease over a Period of 2... not-yet-due
Ongoing 2020-004300-34 A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects with Moderately to Severely Active Ulcerative Coli... not-yet-due
Ongoing 2021-000251-39 A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With ... not-yet-due
Trial is outside EEC 2021-002051-10 A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients with Status Epilepticus (Convulsive) in Community Settings bad-data

Related organisations

Over time organisations can merge, or split.

We think Takeda is now also responsible for the trials of: